Mikrobiomanalytik bei Patienten mit chronisch entzündlichen Darmerkrankungen – spannend, aber schon relevant für die Praxis?

• Literatur

• 1 Ott SJ, Musfeldt M, Wenderoth DF. et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 2004; 53: 685-693
• 2 Nguyen LH, Ortqvist AK, Cao Y. et al. Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden. The lancet Gastroenterology & hepatology 2020; 5: 986-995
• 3 Lange K, Buerger M, Stallmach A. et al. Effects of Antibiotics on Gut Microbiota. Digestive diseases 2016; 34: 260-268
• 4 Moltzau Anderson J, Lipinski S, Sommer F. et al. NOD2 Influences Trajectories of Intestinal Microbiota Recovery After Antibiotic Perturbation. Cell Mol Gastroenterol Hepatol 2020; 10: 365-389
• 5 Vandeputte D, Kathagen G, D’Hoe K. et al. Quantitative microbiome profiling links gut community variation to microbial load. Nature 2017; 551: 507-511
• 6 Aden K, Rehman A, Waschina S. et al. Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases. Gastroenterology 2019; 157: 1279-1292 e1211